Unknown

Dataset Information

0

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.


ABSTRACT: Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in combination with gefitinib in NSCLC cells. We undertook a genome-wide RNAi screen to identify synthetic lethality with gefitinib in tyrosine kinase inhibitor resistant cells. The screening data were utilized in different approaches. Firstly, we identified PRKCSH as a candidate gene, silencing of which induces apoptosis of NSCLC cells treated with gefitinib. Next, in an in silico gene signature pathway analysis of shRNA library data, a strong correlation of genes involved in the CD27 signaling cascade was observed. We showed that the combination of dasatinib (NF-?B pathway inhibitor) with gefitinib synergistically inhibited the growth of NSCLC cells. Lastly, utilizing the Connectivity Map, thioridazine was identified as a top pharmaceutical perturbagen. In our experiments, it synergized with gefitinib to reduce p-Akt levels and to induce apoptosis in NSCLC cells. Taken together, a pooled short-hairpin library screen identified several potential pathways and drugs that can be therapeutic targets for gefitinib resistant NSCLC.

SUBMITTER: Sudo M 

PROVIDER: S-EPMC4359257 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.

Sudo Makoto M   Mori Seiichi S   Madan Vikas V   Yang Henry H   Leong Geraldine G   Koeffler H Phillip HP  

Oncotarget 20150101 2


Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in combination with gefitinib in NSCLC cells. We undertook a genome-wide RNAi screen to identify synthetic lethality with gefitinib in tyrosine kinase inhibitor resistant cells. The screening data were utilized in different approaches. Firstly, we  ...[more]

Similar Datasets

| S-EPMC4317907 | biostudies-other
| S-EPMC2748426 | biostudies-literature
| S-EPMC3636434 | biostudies-literature
| S-EPMC3324507 | biostudies-literature
| S-EPMC5943475 | biostudies-literature
2012-08-31 | E-GEOD-32261 | biostudies-arrayexpress
| S-EPMC3110340 | biostudies-literature
2012-08-31 | GSE32261 | GEO
| S-EPMC4169796 | biostudies-literature
| S-EPMC4186824 | biostudies-literature